{"Clinical Trial ID": "NCT00121836", "Intervention": ["INTERVENTION 1:", "- Capecitabine + Bevacizumab (Bev); Paclitaxel or Vinorelbine +Bev", "The treatment phase of the first study:", "- Capecitabine 1000 mg/m2 orally (PO) twice daily, Days 1 to 15 of each 3-week cycle (28 doses per cycle); bevacizumab 15 mg/kg intravenous infusion (IV), Day 1 of each 3-week cycle.", "Second phase of treatment of the study:", "Paclitaxel 80 mg/m2 60-minute IV infusion (with appropriate premedication), days 1, 8 and 15 of each 4-week cycle (28 days).", "Vinorelbine 25 mg/m2 IV infusion 10-20 minutes, days 1, 8 and 15 of each 4-week cycle.", "Bevacizumab 10 mg/kg IV infusion, days 1 and 15 of each 4-week cycle."], "Eligibility": ["Incorporation criteria:", "Women >=18 years", "HER2-negative metastatic breast cancer", "Previous adjuvant chemotherapy or hormonal treatment", "- Measurable target lesion >=1", "- Exclusion criteria:", "Previous chemotherapy treatment, anti-angiogenic agent or biological therapy for advanced or metastatic cancer", "Radiotherapy within 4 weeks of initiation of study therapy or insufficient recovery of the effects of prior radiation therapy", "Metastasis of the central nervous system", "Other malignancies in the last 5 years, with the exception of basal cell carcinomas of the skin and in situ cervix carcinomas", "\u2022 Concomitant serious infections"], "Results": ["Performance measures:", "Overall survival", "Overall survival was defined as the time between the date of the first treatment dose (day 1) and the date of death, during the study phases, regardless of the cause of death.", "Duration: approximately 505 days (median time to death)", "Results 1:", "Title of arm/group: Capecitabine + Bevacizumab (Bev); Paclitaxel or Vinorelbine +Bev", "Description of the arm/group: First phase of treatment:", "- Capecitabine 1000 mg/m orally (PO) twice daily, Days 1 to 15 of each 3-week cycle (28 doses per cycle); bevacizumab 15 mg/kg intravenous infusion (IV), Day 1 of each 3-week cycle.", "Second phase of treatment of the study:", "Paclitaxel 80 mg/m 60-minute IV infusion (with appropriate premedication), days 1, 8 and 15 of each 4-week cycle (28 days). Paclitaxel substitution with docetaxel was not permitted.", "Vinorelbine 25 mg/m IV infusion 10-20 minutes, days 1, 8 and 15 of each 4-week cycle.", "Bevacizumab 10 mg/kg IV infusion, days 1 and 15 of each 4-week cycle.", "Total number of participants analysed: 109", "Median (95% confidence interval)", "Unit of measurement: Days 505 (420 to 672)"], "Adverse Events": ["Undesirable Events 1:", "Total: 39/109 (35.78 per cent)", "Febrile Neutropenia1/109 (0.92%)", "- Left ventricular failure1/109 (0.92%)", "\u2022 Nausea3/109 (2.75%)", "- Vomitings3/109 (2.75%)", "Abdominal pain1/109 (0.92%)", "- Caecitis1/109 (0.92%)", "Diarrhoea1/109 (0.92%)", "Enterovesic fistula1/109 (0.92%)", "Gastric ulcer1/109 (0.92%)", "Pancreatitis1/109 (0.92%)", "Pain6/109 (5.50%)", "Thoracic pain3/109 (2.75%)"]}